-
Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rateSardu C, Paolisso P, Sacra C et al. -
Dilated cardiomyopathy: so many cardiomyopathies!G Sinagra, PM Elliott, M Merlo et al.
-
Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 InhibitorsS Verma, S Rawat, KL Ho et al.
-
Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-AnalysisW Masson, A Lavalle-Cobo, JP Nogueira et al.
-
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesWriting Committee Members, PA Heidenreich, B Bozkurt et al.
-
INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection FractionA Samman-Tahhan, JS Hedley, AA. McCue et al.
-
Lifestyle Modifications for Preventing and Treating Heart FailureM Aggarwal, B Bozkurt, on behalf of American College of Cardiology’s Nutrition and Lifestyle Committee of the Prevention of Cardiovascular Disease Council.
-
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-ReducedF Zannad, JP Ferreira, SJ Pocock et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
